Genmab Announces 2007 First Half Year Results

Summary: Genmab reports results for the six month period ended June 30, 2007.   

Copenhagen, Denmark; August 21, 2007 - Genmab A/S (OMX: GEN) announced today    
results for the six month period ended June 30, 2007. During this period, Genmab
reported the following results:                                                 

Genmab's revenues were DKK 279.6 million (approx. USD 50.7 million) for the     
first half of 2007. In the same period of 2006, Genmab recognized DKK 74.3      
million (approx. USD 13.5 million) in revenues.                                 

An Operating Loss of DKK 118.9 million (approx. USD 21.6 million). This compares
to an Operating Loss of DKK 187.5 million (approx. USD 34.0 million) reported   
for the corresponding period of 2006.                                           

Net Financial Income totaled DKK 31.8 million (approx. USD 5.8 million),        
compared to Net Financial Expenses of DKK 2.3 million (approx. USD 0.4 million) 
in the first six months of 2006. Net Financial Income has benefited from the    
higher average cash position, whereas the negative net financial income reported
for the first half of 2006 was impacted by increasing interest rates and        
weakening of the USD against the DKK.                                           

A Net Loss of DKK 87.0 million (approx. USD 15.8 million) compared to a Net Loss
of DKK 189.8 million (approx. USD 34.4 million) for the same period in 2006. The
Net Loss per share was DKK 2.01 (approx. USD 0.36) for the first half of 2007   
compared to DKK 4.96 (approx. USD 0.90) in the first half of 2006.              

Genmab ended the six month period with a cash position of DKK 3.980 billion     
(approx. USD 722 million), which is a net increase of DKK 2.256 million (approx.
USD 409.4 million) from the end of 2006.                                        

Highlights                                                                      
During the second quarter of 2007, Genmab achieved a number of business and     
scientific milestones, as follows:                                              

On June 29, Genmab regained all rights to HuMax-CD4® (zanolimumab) from Merck   
Serono S.A. and announced final data from the HuMax-CD4 Phase II data in        
cutaneous T-cell lymphoma (CTCL).                                               

On June 18, Genmab announced further development plans for HuMax-CD20®          
(ofatumumab), including clinical expansion into the new disease indications of  
multiple sclerosis and diffuse large B-cell lymphoma (DLBCL).                   

Effective June 18, Genmab became a member of the OMXC20 index on the OMX Nordic 
Exchange Copenhagen.                                                            

Genmab and GlaxoSmithKline reported positive results from the Phase II study of 
HuMax-CD20 in rheumatoid arthritis (RA) on June 15. These positive results      
triggered the first milestone payment to Genmab in the companies' collaboration.

On June 14, we announced initiation of a Phase II study of HuMax-CD20 in        
combination with CHOP chemotherapy in previously untreated follicular           
non-Hodgkin's lymphoma (NHL) patients.                                          

On June 3, Genmab presented positive pre-clinical data illustrating the broad   
potential of HuMax-EGFr™ for the treatment of cancer.                           

On May 21, Genmab announced positive data showing that HuMax-HepC™ prevented    
Hepatitis C infection in a pre-clinical study.                                  

On April 12, Genmab initiated a Phase II study of HuMax-EGFr in combination with
chemo-radiation to treat non small cell lung cancer.                            

Outlook                                                                         
Genmab is maintaining its financial guidance for the year. We project a 2007    
operating loss of DKK 385 to 435 million and a net loss in the range of DKK 260 
to 310 million. The company's projected December 31, 2007 cash position is      
expected to be in the range of DKK 3.8 to 3.9 billion.                          

Conference Call                                                                 
Genmab will hold a conference call to discuss the first quarter results         
tomorrow, Wednesday, August 22, 2007, at                                        

3.00 pm CEST                                                                    
2.00 pm BST                                                                     
9.00 am EDT                                                                     

The conference call will be held in English.                                    

The dial in numbers are as follows:                                             

+ 1 800 475 3716 (in the US) and ask for the Genmab conference call             
+1 719 457 2728 (outside the US) and ask for the Genmab conference call         

A live webcast of the call and relevant slides will be available at             
www.genmab.com.  The webcast will also be archived on Genmab's website.         




About Genmab A/S                                                                
Genmab is a leading international biotechnology company focused on developing   
fully human antibody therapeutics for unmet medical needs.  Using unique,       
cutting-edge antibody technology, Genmab's world class discovery and development
teams have created and developed an extensive pipeline of products for potential
treatment of a variety of diseases including cancer and autoimmune disorders.   
As Genmab advances towards a commercial future, we remain committed to our      
primary goal of improving the lives of patients who are in urgent need of new   
treatment options.  For more information on Genmab's products and technology,   
visit www.genmab.com.                                                           

This press release contains forward looking statements. The words “believe”,    
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify    
forward looking statements. Actual results or performance may differ materially 
from any future results or performance expressed or implied by such statements. 
The important factors that could cause our actual results or performance to     
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical   
trials including unforeseen safety issues, uncertainties related to product     
manufacturing, the lack of market acceptance of our products, our inability to  
manage growth, the competitive environment in relation to our business area and 
markets, our inability to attract and retain suitably qualified personnel, the  
unenforceability or lack of protection of our patents and proprietary rights,   
our relationships with affiliated entities, changes and developments in         
technology which may render our products obsolete, and other factors. Genmab is 
not under an obligation to up-date statements regarding the future following the
publication of this release; nor to confirm such statements in relation to      
actual results, unless this is required by law.                                 

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R);  
HuMax-EGFr(TM); HuMax-Inflam(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM);
HuMax-ZP3(TM); and UniBody(TM) are all trademarks of Genmab A/S.                

Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M: 
+45 25 27 47 13, E: hth@genmab.com                                              
                                                                                
Stock Exchange Release no. 36/2007                                              

###